Aim: To compare the effects of low-dose alpha-interferons with those of cytostatics (hydroxyurea or myelosan) on survival of patients and duration of chronic phase of chronic myeloid leukemia (CML).
Material And Methods: 107 CML patients were divided into two groups. 28 patients (15 males and 13 females) aged 17-59 entered group treated with alpha-interferon drugs. 79 control patients (35 males and 44 females) aged 15-79 received standard chemotherapy (hydroxyurea or myelosan).
Results: 3-year survival in the study group and controls was 94 and 67.5%, respectively. 5-year survival--70.8 and 28.9%, respectively. The survival medians for the groups were 66 and 48 months, respectively. 36 months after CML diagnosis, chronic phase of the disease still continued in 90.2% of the study group patients and in 53.4% of patients on chemotherapy. 54 months after the diagnosis the chronic phase was registered in 56.5 and 24% of patients, respectively. The medians made up 54 and 39 months, respectively.
Conclusion: Treatment of CML with low-dose alpha-interferons increases duration of the CML chronic phase and survival of CML patients.
Download full-text PDF |
Source |
---|
Liver Int
February 2025
Department of Gastroenterology, Hepatology, Endocrinology, and Infectious Diseases, Hannover Medical School, Hannover, Germany.
Background And Aim: Bulevirtide (BLV) leads to beneficial virologic and biochemical responses when given alone to treat hepatitis delta virus (HDV) infection, which causes the most severe form of chronic viral hepatitis. We evaluated 48 weeks of BLV monotherapy, BLV + tenofovir disoproxil fumarate (TDF) and BLV + pegylated interferon alfa-2a (Peg-IFNα-2a), with 24-week follow-up.
Methods: Ninety patients were enrolled into six arms of 15 each (A-F); 60 patients were included in the main randomisation (arms A-D), and 30 patients (arms E-F) were randomised to the extension phase: (A) Peg-IFNα-2a 180 μg once weekly (QW); (B) BLV 2 mg once daily (QD) + Peg-IFNα-2a 180 μg QW; (C) BLV 5 mg QD + Peg-IFNα-2a 180 μg QW; (D) BLV 2 mg QD; (E) BLV 10 mg QD + Peg-IFNα-2a 180 μg QW and (F) BLV 10 mg (5 mg twice daily) + TDF QD.
Brain Imaging Behav
January 2025
School of Medicine, Pusan National University, Yangsan, Republic of Korea.
COVID-19 disease, caused by the SARS-CoV-2 virus, has significantly altered modern society and lifestyles. We investigated its impact on brain glucose metabolism by meta-analyzing existing studies that utilized 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) scans of the brain. We conducted a systematic search of MEDLINE and EMBASE databases from inception to August 2024 for English-language publications using the keywords "positron emission tomography", and "COVID-19".
View Article and Find Full Text PDFNeurol Int
January 2025
Laboratório de Marcha, Centro de Medicina de Reabilitação de Alcoitão, 2649-506 Alcabideche, Portugal.
Background/objectives: Post-stroke hemiparetic gait often presents with asymmetric patterns to compensate for stability deficits. This study examines gait differences in chronic stroke patients with spastic hemiparesis based on initial foot contact type-forefoot versus rearfoot.
Methods: Thirty-four independently walking spastic hemiparetic patients were retrospectively analyzed.
Nurs Rep
January 2025
Nursing School of Lisbon, 1990-096 Lisbon, Portugal.
Parents who accompany their children with a complex chronic illness until their death experience a unique situation, with vulnerabilities, specific needs and enormous suffering. The aim of the study was to describe the lived experience of parents who accompanied their children with a complex chronic illness until their death, in a paediatric palliative care setting. : We opted for a qualitative methodology, with a descriptive phenomenological orientation.
View Article and Find Full Text PDFBrain Sci
December 2024
College of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.
Background/objectives: Noninvasive brain stimulation (NIBS) can boost motor recovery after a stroke. Certain movement phases are more responsive to NIBS, so a system that auto-detects these phases would optimize stimulation timing. This study assessed the effectiveness of various machine learning models in identifying movement phases in hemiparetic individuals undergoing simultaneous NIBS and EEG recordings.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!